Clinical Trials Logo

Filter by:
NCT ID: NCT05133804 Recruiting - Clinical trials for Posttraumatic Stress Disorder

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.

NCT ID: NCT05122013 Recruiting - Obesity Clinical Trials

Remote Intervention for Weight Regain After Sleeve Gastrectomy

Start date: February 23, 2022
Phase: N/A
Study type: Interventional

The study is designed to assess the effect of a 3-month remote comprehensive intervention program by a multidisciplinary team combined with mobile supportive text messages aimed to raise the level of happiness and subjective wellbeing, on weight outcomes and physical and behavioral parameters among bariatric surgery patients after sleeve gastrectomy who had a weight regain of ≥10% from nadir, compared to a control group which will receive standard care of a single meeting with the study's registered dietitian at the clinic and then be advised to continue follow up.

NCT ID: NCT05117034 Recruiting - Anesthesia Clinical Trials

Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain.

Start date: February 16, 2022
Phase: N/A
Study type: Interventional

We propose a double-blind randomized controlled trial to evaluate the effect of intravenously administered morphine at surgery conclusion on acute postoperative pain in patients recovering from craniotomy surgery. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.

NCT ID: NCT05111626 Recruiting - Gastric Cancer Clinical Trials

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer

FORTITUDE-102
Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.

NCT ID: NCT05106504 Recruiting - Parkinson Disease Clinical Trials

Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease

Start date: September 2, 2021
Phase:
Study type: Observational

Medical cannabis (MC) is a standard treatment in Israel to Parkinson's disease (PD) patients suffering from pain. Nevertheless, it is not known about MC effectiveness for other non-motor symptoms of the disease. Our aim is to prospectively observe patients with PD before and after initiation of MC, for non-motor symptoms effect. In specific, relying of data from multiple sclerosis patients and basic science showing cannabinoid receptor 1 (CB1) is abundantly expressed in the sub epithelial layer of the bladder, we will explore the impact of MC on bladder function and urinary symptoms.

NCT ID: NCT05105113 Recruiting - Dental Implantation Clinical Trials

Evaluation of Survival and Success Rates of Zirzonia Dental Implants

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Survival and success rates of Zirconia dental implants compared with Titanium implants (Two-Piece Zirconia implants)

NCT ID: NCT05104827 Recruiting - Clinical trials for Wellbeing of Healthcare Providersin Frontline COVID-19 Departments

Integrative Medicine Impact on Frontline COVID-19 Personnel Wellbeing

Start date: December 31, 2020
Phase: N/A
Study type: Interventional

Treating COVID-19 hospitalized patients incurred heavy burden of physical and emotional stress. The present study is taking place at Carmel Medical Center in collaboration with the integrative oncology and the internal medicine teams with aim to improve the wellbeing of healthcare providers working in frontline COVID-19 departments. In this prospective preference study, Healthcare providers (HCPs) working inside COVID-19 departments are referred to integrative oncology-trained practitioners for assessment of their two leading concerns followed by 30-minute individually tailored treatment. The study assess, based on the Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire, the impact of personalized integrative oncology modalities on the physical and emotional concerns as well as Heart Rate Variability of participating HCPs in COVID-19 departments.

NCT ID: NCT05103371 Recruiting - Primary Prevention Clinical Trials

A Prevention Program to Encourage Self-care, Self-esteem and Body-esteem Among Young Adolescents

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Cluster-Randomized Clinical trial, which includes the development and activation of an intervention program among young adolescents and their parents. Study hypothesis is that the intervention program will yield improvement in adolescents whose parents participated in the program, in comparison with the adolescents whose parents weren't involved in the intervention. Results will be measured using the study questionnaire, to be filled out by the participants before, after, and three months after the completion of the program. The questionnaire will include validated questionnaires with good psychometric qualities. The study protocol was approved by Tel Hai College institutional review board. Parents of all participants, in the intervention and in the control group, received information about the program and the study and were asked to provide informed consent.

NCT ID: NCT05101187 Recruiting - Clinical trials for Invasive Aspergillosis

Olorofim Aspergillus Infection Study

OASIS
Start date: March 31, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

NCT ID: NCT05100862 Recruiting - Clinical trials for Marginal Zone Lymphoma

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

MAHOGANY
Start date: March 10, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.